



## Oral Programme

Sunday 27 October

08:30 – 10:15	<b>Congress Registration – Tramuntana Foyer, -1 Floor</b> Coffee will be served during registration
10:15 – 12:25	<b>Opening Session &amp; Plenary Session 1 - Vaccine science in Spain</b> Chairs: Adolfo Garcia & Mariano Esteban Room: Auditorium, 0 Floor
10:15 – 10:25	<b>Opening Remarks:</b> Adolfo Garcia-Sastre <sup>1</sup> , Mariano Esteban <sup>1</sup> , Floris de Hon <sup>2</sup> , <sup>1</sup> Congress Co-Chairs, <sup>2</sup> Publishing Director, Elsevier
10:25 – 11:05	<b>[O1.1] Malaria vaccine: How far</b> P. Alonso, <i>Barcelona Institute for Global Health, Spain</i>
11:05 – 11:45	<b>[O1.2] Dendritic cell based vaccines</b> J. Gatell, <i>University of Barcelona, Spain</i>
	<b>Plenary Session 1 Continued - Future science of vaccines</b> Chairs: Adolfo Garcia & Mariano Esteban Room: Auditorium, 0 Floor
11:45 – 12:10	<b>[O1.3] Designing vaccines for the 21st century society</b> R. Rappuoli, <i>Novartis, Italy</i>
12:10 – 12:35	<b>[O1.4] Influenza vaccine failure: What is it and how does it occur?</b> G. A. Poland, <i>Mayo Clinic, USA</i>
12:35	<b>All posters can be mounted in the Tramuntana Room, -1 Floor</b>
12:35 – 13:30	<b>Lunch – Tramuntana Room, -1 Floor</b>
13:30 – 15:30	<b>Plenary Session 2 - Influenza vaccines</b> Chairs: Ted Ross & Polly Roy Room: Auditorium, 0 Floor
13:30 – 13:55	<b>[O2.1] Emerging virus infections and novel intervention strategies</b> A. Osterhaus, <i>The Erasmus University Medical Center, Netherlands</i>
13:55 – 14:20	<b>[O2.2] What determines influenza vaccine protection (and how effective are the vaccines)</b> A. Monto, <i>University of Michigan, USA</i>
14:20 – 14:30	<b>[O2.3] Scale-up and technology transfer for the protein sciences recombinant influenza vaccine (Flublok)</b> B.C. Buckland*, R. Boulanger, M. Fino, S. Vaspory, N. Khramtsov, J. Meghrous, A. Price, C. McPherson, I. Srivastava, M. Cox, <i>Protein Sciences, USA</i>
14:30 – 14:40	<b>[O2.4] Rapid response to influenza pandemics using synthetic vaccine seed viruses</b> P.W. Mason* <sup>1</sup> , P. Suphaphiphat <sup>1</sup> , P. Dormitzer <sup>1</sup> , D. Gibson <sup>2</sup> , D. Wentworth <sup>2</sup> , T. Stockwell <sup>2</sup> , A. Donabedian <sup>3</sup> , J. Glass <sup>2</sup> , R. Rappuoli <sup>1</sup> , J.C. Venter <sup>2</sup> , <sup>1</sup> Novartis Vaccines and Diagnostics, USA, <sup>2</sup> JCVI, USA, <sup>3</sup> BARDA, USA
14:40 – 14:50	<b>[O2.5] A universal influenza virus vaccine based on the stalk domain of the hemagglutinin</b> I. Margine*, F. Krammer, N. Pica, R. Hai, P. Palese, <i>Icahn School of Medicine at Mount Sinai, USA</i>
14:50 – 15:00	<b>[O2.6] Protective immunization against H1N1 influenza A with spray-dried and electron-beam sterilized vaccines in non-human primates</b> R. Scherliess <sup>1</sup> , M. Dennis <sup>2</sup> , M. Carroll <sup>2</sup> , J. Altrichter <sup>3</sup> , A. Ajmera <sup>1</sup> , N. Silman <sup>1</sup> , M. Scholz* <sup>3</sup> , K. Kemter <sup>3</sup> , A. Marriott <sup>2</sup> , <sup>1</sup> Christian Albrecht University Kiel, Germany, <sup>2</sup> Public Health England, UK, <sup>3</sup> LEUKOCARE AG, Germany
15:00 – 15:10	<b>[O2.7] Induction of potent CTL activity for cancer immunotherapy: Development of VGX-3100 for HPV associated cancers and hTERT DNA vaccine for solid tumors</b> J. Yan <sup>1</sup> , M.P. Morrow <sup>1</sup> , P. Pankhong <sup>2</sup> , T. Shin <sup>2</sup> , N. Obeng-Adjei <sup>2</sup> , J.N. Walters <sup>2</sup> , A.S. Khan <sup>1</sup> , M. Bagarazzi <sup>1</sup> , D.B. Weiner <sup>2</sup> , N.Y. Sardesai* <sup>1</sup> , <sup>1</sup> Inovio Pharmaceuticals, Inc., USA, <sup>2</sup> University of Pennsylvania, USA
15:10 – 15:20	<b>[O2.8] Plant-made virus-like particle vaccines for influenza: Advantages in speed and induction of a broad immune response</b> N. Landry* <sup>1</sup> , S. Trépanier <sup>1</sup> , M.A. D'Aoust <sup>1</sup> , M. Bérubé <sup>1</sup> , M. Couture <sup>1</sup> , E. Aubin <sup>1</sup> , S. Pillet <sup>1,2</sup> , B.J. Ward <sup>2</sup> , <sup>1</sup> Medicago inc., Canada, <sup>2</sup> Research Institute of the McGill University Health Centre University, Canada
15:20 – 15:30	<b>[O2.9] Immune history shapes specificity of pandemic H1N1 influenza antibody responses</b> D.M. Carter* <sup>1</sup> , C.J. Crevar <sup>1</sup> , Y. Li <sup>2,3</sup> , J. Wrammert <sup>4</sup> , S. Esposito <sup>5</sup> , R. Ahmed <sup>4</sup> , P.C. Wilson <sup>6</sup> , S.E. Hensley <sup>2</sup> , T.M. Ross <sup>1</sup> , <sup>1</sup> Vaccine and Gene Therapy Institute of Florida, USA, <sup>2</sup> Wistar Institute, USA, <sup>3</sup> University of Pennsylvania, USA, <sup>4</sup> Emory University, USA, <sup>5</sup> Universita degli Studi di Milano, Italy, <sup>6</sup> University of Chicago, USA

15:30 – 16:00	<b>Refreshment Break – Tramuntana Room, -1 Floor</b>
16:00 – 17:50	<b>Plenary Session 3 - Zoonotics pathogens and veterinary vaccines</b> Chairs: Marc Girard & Tony Fooks Room: Auditorium, 0 Floor
16:00 – 16:25	<b>[O3.1] Vaccines and development for human and animal health</b> J.L. Heeney, <i>University of Cambridge, UK</i>
16:25 – 16:50	<b>[O3.2] Structure-based designer vaccines for orbiviruses</b> P. Roy, <i>Department of Pathogen Molecular Biology, UK</i>
16:50 – 17:00	<b>[O3.3] Tick ferritin 2 - the promising candidate antigen for development of an efficient veterinary anti-tick vaccine</b> P. Kopacek <sup>1</sup> , O. Hajdusek <sup>1</sup> , J. Nepereny <sup>2</sup> , R. Sima <sup>1</sup> , V. Vrzal <sup>2</sup> , J. de la Fuente <sup>3</sup> , <sup>1</sup> <i>Biology Centre Academy of Sciences, Czech Republic</i> , <sup>2</sup> <i>Bioveta a.s., Ivanovice na Hane, Czech Republic</i> , <sup>3</sup> <i>IREC-CSIC-UCLM-JCCM, Spain</i>
17:00 – 17:10	<b>[O3.4] Field trials of Staphylococcus aureus avirulent vaccine against bovine mastitis under natural infection in dairy farm</b> M. Richardet, C. Vissio, M. Pellegrino, A. Larriestra, M. Lasagno, J. Giraud, C. Raspanti, L. Odierno, C. Bogni*, <i>Universidad Nacional de Río Cuarto, Argentina</i>
17:10 – 17:20	<b>[O3.5] Recombinant vaccines against African horse sickness virus (AHSV) based on modified vaccinia ankara (MVA) expressing AHSV-VP2: Effector mechanisms of immunity</b> J. Castillo-Olivares <sup>1</sup> , E. Calvo-Pinilla <sup>1</sup> , N. Manning <sup>1</sup> , F. de la Poza <sup>2</sup> , K. Bachanek-Bankowska <sup>1</sup> , J. Ortego <sup>2</sup> , P. Mertens <sup>1</sup> , <sup>1</sup> <i>Pirbright Institute, UK</i> , <sup>2</sup> <i>CISA-INIA, Spain</i>
17:20 – 17:30	<b>[O3.6] Cross-protection against cutaneous and visceral leishmaniasis using the hisak70 vaccine</b> G. Domínguez-Bernal <sup>1</sup> , P. Horcajo <sup>1</sup> , J.A. Orden <sup>1</sup> , R. De La Fuente <sup>1</sup> , L. Ordóñez-Gutiérrez <sup>2</sup> , J. Carrión <sup>1</sup> , <sup>1</sup> <i>Complutense University of Madrid, Spain</i> , <sup>2</sup> <i>Molecular Biology Centre CSIC-UAM, Spain</i>
17:30 – 17:40	<b>[O3.7] The antibody immunosignature on a random peptide microarray predicts vaccine efficacy</b> J.B. Legutki*, S.A. Johnston, <i>Arizona State University, USA</i>
17:40 – 17:50	<b>[O3.8] Influence of vaccination strategies on IgG Fc glycosylation</b> A. Winkler <sup>1</sup> , C. Hess <sup>1</sup> , C.M. Oefner <sup>1</sup> , D. Petzold <sup>2,4</sup> , M. Berger <sup>2</sup> , H. Wardemann <sup>3</sup> , M. Ehlers <sup>1,4</sup> , <sup>1</sup> <i>German Rheumatism Research Center, Germany</i> , <sup>2</sup> <i>University Medicine Berlin, Germany</i> , <sup>3</sup> <i>Max-Planck-Institute for Infection Biology, Germany</i> , <sup>4</sup> <i>University of Luebeck, Germany</i>
17:50 – 18:00	<b>[O3.9] Best practices in nucleic acid removal from vaccine processes</b> F. Appel <sup>1</sup> , P. Pattnaik <sup>2</sup> , <sup>1</sup> <i>Merck Millipore, Germany</i> , <sup>2</sup> <i>Merck Pte. Ltd., Singapore</i>
18:00 – 19:00	<b>Welcome Drinks Reception - Kindly Sponsored by EpiVax – Tramuntana Room, -1 Floor</b> <b>Poster Session 1 – all odd poster numbers to present (P1, P3, P5 etc.)</b>
<b>Monday 28 October</b>	
08:00 – 08:30	<b>Congress Registration</b>
08:30 – 10:30	<b>Plenary Session 4 - Vaccines for global health</b> Chairs: Rino Rappuoli & Shan Lu Room: Auditorium, 0 Floor
08:30 – 08:55	<b>[O4.1] MTBVAC, first live-attenuated M. tuberculosis-based vaccine: From the lab to the clinical trial</b> C. Martin, <i>University of Zaragoza, Spain</i>
08:55 – 09:20	<b>[O4.2] Current and future perspectives of HIV vaccines</b> G. Pantaleo, <i>University of Lausanne, Switzerland</i>
09:20 – 09:30	<b>[O4.3] Synthetic enhanced EP delivered Ig DNA vector drives biologically relevant Anti-HIV-1 envelope responses in Vivo</b> K. Muthumani <sup>1</sup> , S. Flingai <sup>1</sup> , M. Wise <sup>1</sup> , C. Tingey <sup>1</sup> , E. Reuschel <sup>1</sup> , K. Ugen <sup>2</sup> , D. Weiner <sup>1</sup> , <sup>1</sup> <i>Department of Pathology and Laboratory Medicine, USA</i> , <sup>2</sup> <i>University of South Florida, USA</i>
09:30 – 09:40	<b>[O4.4] Measles-mumps-rubella-vaccination reduces hospital admissions due to non-targeted Infections - A Danish nationwide register based study</b> S. Sorup <sup>1</sup> , C.S. Benn <sup>1,3</sup> , A. Poulsen <sup>4</sup> , T.G. Krause <sup>1</sup> , P. Aaby <sup>1,2</sup> , H. Ravn <sup>1,2</sup> , <sup>1</sup> <i>Statens Serum Institut, Denmark</i> , <sup>2</sup> <i>Bandim Health Project, Guinea-Bissau</i> , <sup>3</sup> <i>University of Southern Denmark, Denmark</i> , <sup>4</sup> <i>Rigshospitalet, Denmark</i>
09:40 – 09:50	<b>[O4.5] TRANSVAC - European network of vaccine research and development</b> C. Dutruel*, M. Geels, R.L. Thøgersen, O. Leroy, <i>European Vaccine Initiative, Germany</i>
09:50 – 10:10	<b>[O4.6] Sustainability of national immunization programme (NIP) performance and financing following global alliance for vaccines and immunization (GAVI) support to the Democratic Republic of the Congo (DRC)</b> J-B. Le Gargasson <sup>1</sup> , J.G. Breugelmans <sup>1</sup> , B. Mibulumukini <sup>2</sup> , A. Da Silva <sup>1</sup> , A. Colombini <sup>1</sup> , <sup>1</sup> <i>Agence de Médecine Préventive, France</i> , <sup>2</sup> <i>SANRU, Democratic Republic of Congo</i>
10:10 – 10:20	<b>[O4.7] Phase I clinical trial of an F-genotype mumps attenuated vaccine</b> Q.H. Li <sup>1</sup> , Y. Liang <sup>1</sup> , L.D. Liu <sup>1</sup> , <sup>1</sup> <i>Chinese Academy of Medicine Science, Peking Union Medical College, China</i> , <sup>2</sup> <i>Hebei Province Center for Disease Control and Prevention, China</i> , <sup>3</sup> <i>National Institutes for Food and Drug Control, China</i> , <sup>4</sup> <i>Fudan University, China</i>

10:20 – 10:30	<b>[O4.8] RSV vaccines for the young and elderly: What is needed to succeed?</b> M. P. M. McCarthy, <i>MedImmune LLC, USA</i>	
10:30 – 11:00	<b>Refreshment Break – Tramuntana Room, -1 Floor</b>	
11:00 – 12:30	<b>Breakout Session 1 - Japanese Society of Vaccines (JSV) joint session</b> Chairs: Hiro Kiyono & Ken Ishi Room: Auditorium, 0 Floor	<b>Breakout Session 2 - Biodefense and neglected disease vaccines</b> Chairs: Arnold Monto & Juergen Richt Room: Garbi, -1 Floor
11:00 – 11:25	<b>[B1.1] Mucorice system for new generation of prophylaxis and therapeutic oral vaccine</b> H. Kiyono <sup>*1</sup> , D. Tokuhara <sup>1</sup> , L. Hammarström <sup>2</sup> , Y. Yuki <sup>1</sup> , <sup>1</sup> <i>The University of Tokyo, Japan</i> , <sup>2</sup> <i>Karolinska University Hospital Huddinge, Sweden</i>	<b>[B2.1] Vector choice for the shaping of vaccine-induced immunity</b> N. Sullivan, <i>NIH/VRC, USA</i>
11:25 – 11:50	<b>[B1.2] Seeking biomarkers and mechanism of vaccine adjuvants; for more effective and safer vaccination</b> K. Ishii <sup>1,2</sup> , <sup>1</sup> <i>National Institute of Biomedical Innovation (NIBIO), Japan</i> , <sup>2</sup> <i>Osaka University, Japan</i>	<b>[B2.2] Combating neglected tropical diseases: the role of product development partnerships in accelerating translation of discoveries into new vaccines</b> M-E. Bottazzi, <i>Baylor College of Medicine, USA</i>
11:50 – 12:00	<b>[B1.3] Development of dsRNAs with low toxicity for application as adjuvants in prophylactic vaccination</b> T. Nakano*, H. Fujita, E. Yamamura, <i>Kyowa Hakko Bio Co., Ltd., Japan</i>	<b>[B2.3] Vaccination with nucleoside hydrolase (NH36) of L. (L.) donovani or its C-terminal portion (F3) in formulation with Saponin prevent the defective migration of dendritic cells in murine experimental visceral leishmaniasis</b> D. Nico, A. Morrot, C.B. Palatnik-de-Sousa*, <i>Federal University of Rio de Janeiro, Brazil</i>
12:00 – 12:10	<b>[B1.4] A novel therapeutic vaccine against tuberculosis in the cynomolgus monkey model and clinical trial</b> M. Okada <sup>*1</sup> , T. Nakajima <sup>2</sup> , Y. Kaneda <sup>3</sup> , E. V.Tan <sup>4</sup> , D. McMurray <sup>5</sup> , Y. Inoue <sup>1</sup> , K. Tomono <sup>3</sup> , A. Kumanogoh <sup>3</sup> , K. Tsuyuguchi <sup>1</sup> , S. Syoji <sup>6</sup> , <sup>1</sup> <i>National Hospital Organization Kinki-Chuo Chest Medical Center, Japan</i> , <sup>2</sup> <i>Genomidea Co, Japan</i> , <sup>3</sup> <i>Osaka University, Japan</i> , <sup>4</sup> <i>Leonard Wood Memorial Institute, The Philippines</i> , <sup>5</sup> <i>Texas A&amp;M University, USA</i> , <sup>6</sup> <i>NHO Tokyo Hospital, Japan</i>	<b>[B2.4] Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage</b> A. De Groot, <i>EpiVax, Inc, USA</i>
12:10 – 12:20	<b>[B1.5] Hemozoin as a novel particulate vaccine adjuvant</b> C.C. Coban <sup>*1</sup> , S.A. Akira <sup>1</sup> , K.J.I. Ishii <sup>1,2</sup> , <sup>1</sup> <i>Osaka University, Japan</i> , <sup>2</sup> <i>National Institute of Biomedical Innovation (NIBIO), Japan</i>	<b>[B2.5] Experimental Chagas' disease: Therapeutic vaccination with Trypanosoma rangeli modulates the antibody response and help to control infection with Trypanosoma cruzi</b> B. Basso <sup>*1,2</sup> , G. Irrazabal <sup>2</sup> , E. Moretti <sup>2,1</sup> , <sup>1</sup> <i>National University of Córdoba, Argentina</i> , <sup>2</sup> <i>National Service of Chagas' Disease, Argentina</i>
12:20 – 12:30	<b>[B1.6] Second generation COBRA vaccines against emerging (H5N1, H7N9, H1N1) and seasonal (H1N1) influenza viruses</b> T.M. Ross <sup>1</sup> , C.J. Crevar <sup>1</sup> , D.M. Carter <sup>*1</sup> , S.J. Bissel <sup>2</sup> , C.A. Wiley <sup>2</sup> , <sup>1</sup> <i>Vaccine and Gene Therapy Institute of Florida, USA</i> , <sup>2</sup> <i>University of Pittsburgh, USA</i>	<b>[B2.6] Prophylactic efficacy of three generations of subunit vaccines against Trypanosoma cruzi and Chagas disease</b> S. Gupta <sup>1</sup> , V. Bhatia <sup>1</sup> , M. Sinha <sup>1</sup> , J. Vazquez <sup>2</sup> , B. Luxon <sup>1</sup> , N. Garg <sup>*1</sup> , <sup>1</sup> <i>University of Texas Medical Branch, USA</i> , <sup>2</sup> <i>Centro de Investigación y Estudios Avanzados en Salud Animal, Mexico</i>
12:30 – 14:00	<b>Lunch – Tramuntana Room, -1 Floor</b>	
13:30 – 14:30	<b>Vaccine Author Workshop – Garbi Room, -1 Floor</b> F. de Hon, A. Helseloot, <i>Elsevier, The Netherlands</i>	
14:00 – 15:00	<b>ISV Annual General Meeting (open) – Auditorium, 0 Floor</b> Chair: Shan Lu, ISV president	
14:30 – 15:30	<b>Poster Session 2 – all even poster numbers to present (P2, P4, P6 etc.) – Tramuntana Room, -1 Floor</b>	
15:30 – 17:30	<b>Plenary Session 5 - Vaccine adjuvants and vaccine safety</b> Chairs: Annie DeGroot & Ray Spier Room: Auditorium, 0 Floor	
15:30 – 15:55	<b>[O5.1] Saponin based adjuvants are proving to be an effective option for the development of new vaccines</b> E. Maraskovsky, <i>CSL Limited, Australia</i>	

15:55 – 16:20	<b>[O5.2] Vaccination and autoimmunity</b> P. H. Lambert, <i>University of Geneva, Switzerland</i>
16:20 – 16:30	<b>[O5.3] Adjuvant-induced muscle ATP release potentiates response to vaccination</b> M. Vono <sup>*1,2</sup> , M. Taccone <sup>2</sup> , P. Caccin <sup>1</sup> , M. Gallotta <sup>2</sup> , M. Pallaoro <sup>2</sup> , R. Rappuoli <sup>2</sup> , E. De Gregorio <sup>2</sup> , F. Di Virgilio <sup>3</sup> , C. Montecucco <sup>1</sup> , A. Seubert <sup>2</sup> , <sup>1</sup> <i>University of Padova, Italy</i> , <sup>2</sup> <i>Novartis Vaccines and Diagnostics, Italy</i> , <sup>3</sup> <i>University of Ferrara, Italy</i>
16:30 – 16:40	<b>[O5.4] The RIG-I agonist Sendai virus defective-interfering RNA as a vaccine adjuvant and its mechanism of action</b> J.R. Patel*, L. Martinez-Gil, P.H. Goff, R. Hai, M.L. Shaw, P. Palese, A. Garcia-Sastre, <i>Icahn School of Medicine at Mount Sinai, USA</i>
16:40 – 16:50	<b>[O5.5] Immunogenicity and efficacy of a tetravalent dengue vaccine based on Flagellin-E fusion in mice and monkeys</b> G. Liu <sup>*1</sup> , D. Beasley <sup>2</sup> , L. Song <sup>1</sup> , R. Putnak <sup>3</sup> , J. Parent <sup>1</sup> , J. Mischak <sup>1</sup> , H. Li <sup>1</sup> , X. Liu <sup>1</sup> , W. Liu <sup>1</sup> , L. Trvalent <sup>1</sup> , <sup>1</sup> <i>VaxInnate Corporation, USA</i> , <sup>2</sup> <i>University of Texas Medical Branch, USA</i> , <sup>3</sup> <i>Walter Reed Army Institute of Research, USA</i>
16:50 – 17:00	<b>[O5.6] Immunostimulatory self-assembling peptide epitopes as a novel therapeutic cancer vaccine</b> M. Herbert-Fransen <sup>2</sup> , A. de Graaf <sup>1</sup> , M. Mansourian <sup>1</sup> , M. Krawczyk <sup>1</sup> , F. Ossendorp <sup>2</sup> , M. Amidi <sup>*1</sup> , <sup>1</sup> <i>Utrecht University, The Netherlands</i> , <sup>2</sup> <i>Leiden University Medical Center, The Netherlands</i>
17:00 – 17:10	<b>[O5.7] Immunoadjuvant IL-33 enhances Human Papillomavirus 16 E6/E7-specific cell-mediated immunity and induced potent antitumor immunity</b> D.O. Villarreal <sup>*1</sup> , M.C. Wise <sup>1</sup> , J. Walters <sup>1</sup> , J. Yan <sup>2</sup> , M.P. Morrow <sup>2</sup> , D.B. Weiner <sup>1</sup> , <sup>1</sup> <i>University of Pennsylvania, USA</i> , <sup>2</sup> <i>Inovio Pharmaceuticals, Inc, USA</i>
17:10 – 17:20	<b>[O5.8] Transcriptomic analysis of wild-type and mutant avipoxvirus vaccine vectors</b> M. A. Skinner <sup>*1</sup> , M. Bissa <sup>2</sup> , E. S. Giotis <sup>1</sup> , R. Robey <sup>1</sup> , <sup>1</sup> <i>Imperial College London, UK</i> , <sup>2</sup> <i>State University of Milan, Italy</i>
19:00	<b>Depart the Melia Sitges Hotel to go to the Gala Dinner (ticket holders only)</b>
19:30 – 23:00	<b>Congress Gala Dinner (ticket holders only)</b>
<b>Tuesday 29 October</b>	
08:30 – 08:45	<b>Congress Registration</b>
08:45 – 10:30	<b>Plenary Session 6 - Bacterial vaccines</b> Chairs: Olaf Schneewind & Anton Middelburg Room: Auditorium, 0 Floor
08:45 – 09:10	<b>[O6.1] <i>Staphylococcus aureus</i> immune evasion and vaccine strategies to combat infection</b> O. Schneewind <sup>1,2</sup> , <sup>1</sup> <i>University of Chicago, USA</i> , <sup>2</sup> <i>Great Lakes Center for Excellence for Biodefense &amp; Emerging Infectious Diseases Research, USA</i>
09:10 – 09:20	<b>[O6.2] Towards a one dose glycoconjugate cholera vaccine</b> C. Grandjean <sup>*1</sup> , T.K. Wade <sup>2</sup> , W.F. Wade <sup>2</sup> , <sup>1</sup> <i>University of Nantes, France</i> , <sup>2</sup> <i>Geisel School of Medicine at Dartmouth, USA</i>
09:20 – 09:30	<b>[O6.3] The <i>Yersinia pestis</i> capsule F1 antigen induces rapid humoral anti-plague immunity in a CD4<sup>+</sup> T helper cell independent manner</b> Y. Levy*, Y. Vagima, Y. Flashner, A. Tidhar, A. Zauberman, M. Aftalion, D. Gur, A. Shafferman, E. Mamroud, <i>Israel</i>
09:30 – 09:40	<b>[O6.4] Recombinant outer membrane vesicles as a novel pertussis vaccine</b> A. van der Ark, A. Sloots, M. Meerlo, T. Bindels, B. Kuipers, C. Hoitink, P. van der Ley*, <i>InTraVacc, The Netherlands</i>
09:40 – 09:50	<b>[O6.5] Multi-component vaccines against chlamydia trachomatis elicit different immune outcomes following heterologous vector prime-protein boost immunisations</b> A. Badamchi-Zadeh <sup>*1</sup> , P.F. McKay <sup>1</sup> , F. Follmann <sup>2</sup> , R.J. Shattock <sup>1</sup> , <sup>1</sup> <i>Imperial College London, UK</i> , <sup>2</sup> <i>Statens Serum Institut, Denmark</i>
09:50 – 10:00	<b>[O6.6] A CD8<sup>+</sup> T-cell poly-epitope DNA vaccine engineered on the basis of <i>Francisella tularensis</i> whole-genome immunoinformatic analysis elicits a protective CTL immune response</b> O. Cohen, <i>Israel</i>
10:00 – 10:10	<b>[O6.7] Epitope unmasking by conformational inactivation of the receptor-binding pocket</b> D. Kisiela, E. Sokurenko*, <i>University of Washington, USA</i>
10:10 – 10:20	<b>[O6.8] Higher order epitope patterns in proteins</b> R.D. Bremel*, E.J. Homan, <i>ioGenetics LLC, USA</i>
10:20 – 10:30	<b>[O6.9] On the use of the concept of "fairness" in the world of vaccines and vaccination</b> R. Spier, <i>Emeritus Professor formerly of the University of Surrey, UK</i>
10:30 – 11:00	<b>Refreshment Break</b>

11:00 – 12:30	<b>Breakout Session 3 - Novel vaccine delivery and nanotechnology</b> Chairs: Niranjana Sardesai & Clarisa Palatnik De Sousa Room: Auditorium, 0 Floor	<b>Breakout Session 4 - Vaccines against chronic viral infections</b> Chairs: Maria-Elena Bottazzi & Nancy Sullivan Room: Garbi, -1 Floor
11:00 – 11:25	<b>[B3.1] New vaccine modalities from the biotechnology-nanotechnology nexus</b> A. P. Middelberg*, L. H. L. Lua, <i>The University of Queensland, Australia</i>	<b>[B4.1] High, broad, polyfunctional and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate based on MVA expressing the near full-length HCV genome (MVA-HCV)</b> C.E. Gómez, B. Perdiguero, M.V. Cepeda, L. Mingorance, J. García-Arriaza, A. Vandermeeren C.O. Sorzano, M. Esteban*, <i>CNB-CSIC, Spain</i>
11:25 – 11:50	<b>[B3.2] Strategies for efficient vaccine delivery</b> A.R. Shaw*, A. Li, J. Moon, D. Irvine, <i>Vedantra, USA</i>	<b>[B4.2] A glycoprotein H complex of human cytomegalovirus is the main target for potent neutralizing antibodies</b> T-M Fu, <i>Merck Research Laboratories, USA</i>
11:50 – 12:00	<b>[B3.3] Peptide nanofiber vaccines elicit robust CD8+ T cell responses</b> C.B. Chesson* <sup>1</sup> , E.J. Huelsmann <sup>2</sup> , A.T. Lacey <sup>2</sup> , A. Zloza <sup>2</sup> , J.S. Rudra <sup>1,3</sup> , <sup>1</sup> <i>University of Texas Medical Branch, USA</i> , <sup>2</sup> <i>Rush University Medical Center, USA</i> , <sup>3</sup> <i>Sealy Center for Vaccine Development, USA</i>	<b>[B4.3] The replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust T-cell immunity and broad-spectrum neutralising antibodies in macaques</b> B-W. Wen, Y-D. Deng, H-C. Chen, W-T. Tan*, <i>Ministry of Health and China Centers for Disease Control and Prevention, China</i>
12:00 – 12:10	<b>[B3.4] A novel vaccine delivery system of gel particle with pH sensitivity induces robust humoral and cellular immune responses based on multiple mechanisms</b> G.H. Ma*, Y.Q. Wang, J. Wu, Z.G. Su, <i>Chinese Academy of Sciences, China</i>	<b>[B4.4] A live-attenuated HSV-2 ICPO- virus is avirulent and elicits superior protection against genital herpes</b> W.P. Halford*, J. Geltz, E. Gershburg, <i>Southern Illinois University School of Medicine, USA</i>
12:10 – 12:20	<b>[B3.5] Multifunctional cancer vaccine using ligand-modified nanoparticles</b> J.M. Silva* <sup>1,2</sup> , G. Vancermellen <sup>2</sup> , V.G. Oliveira <sup>1</sup> , S. Pinto <sup>1</sup> , E. Zupancic <sup>1</sup> , L. Graca <sup>1</sup> , V. Pr�eat <sup>2</sup> , H. Florindo <sup>1</sup> , <sup>1</sup> <i>University of Lisbon, Portugal</i> , <sup>2</sup> <i>Universit� catholique de Louvain, Belgium</i>	<b>[B4.5] HCV infection and Hepatocarcinoma: Some perplexities on immune therapy and therapeutic vaccines</b> S.M. Criscione, <i>University of L'Aquila, Italy</i>
12:20 – 12:30	<b>[B3.6] Immunogenicity and efficacy of a freeze-dried compared to a liquid-frozen formulation of MVA-BN<sup>®</sup> in Ectromelia and Vaccinia virus challenge models in BALB/c mice</b> R. Castoldi*, K. Baur, C. Schmittwolf, Y. Wollmann, N.H. Wulff, P. Chaplin, A. Volkman, <i>Bavarian Nordic GmbH, Germany</i>	<b>[B4.6] Immunization status of patients with chronic hepatitis C</b> M. Mateos Mazon* <sup>1</sup> , M.C. Martinez Ortega <sup>1</sup> , M.J. Gonz�lez Garrido <sup>1</sup> , B. Suarez Mier <sup>1</sup> , M.B. Diaz Rodriguez <sup>1</sup> , R. P�rez Alvarez <sup>1,2</sup> , <sup>1</sup> <i>Hospital Universitario Central de Asturias, Spain</i> , <sup>2</sup> <i>Universidad de Oviedo, Spain</i>
12:30 – 14:00	<b>Lunch – Tramuntana Room, -1 Floor</b>	
13:00 – 14:00	<b>Meet the Editors at the Elsevier Exhibition Stand</b>	
14:00	<b>All posters are to be removed</b>	
14:00 – 15:30	<b>Plenary Session 7 - Future vaccine development and congress summary</b> Chairs: Eugene Maraskovsky Room: Auditorium, 0 Floor	
14:00 – 14:20	<b>Edward Jenner Poster Prize Ceremony</b>	
	<b>[O7.1] now [O1.4]</b>	
14:20 – 14:45	<b>[O7.2] NDV-based live influenza vaccine candidates in chickens and pigs</b> Q. Liu <sup>1</sup> , M. Nacho <sup>2</sup> , J. Ma <sup>1</sup> , B. Bawa <sup>1</sup> , Y. Lyoo <sup>1,3</sup> , Y. Lang <sup>1</sup> , J. Lee <sup>1</sup> , H. Shen <sup>1</sup> , Y. Chen <sup>1</sup> , I. Morozov <sup>1</sup> , W. Ma <sup>1</sup> , A. Garcia-Sastre <sup>2</sup> , J.A. Richt* <sup>1</sup> , <sup>1</sup> <i>Kansas State University, USA</i> , <sup>2</sup> <i>Mount Sinai School of Medicine, USA</i> <sup>3</sup> <i>Konkuk University, Seoul Korea</i>	
14:45 - 15:10	<b>[O7.3] Strategies for the elimination of rabies</b> A.R. Fooks <sup>1,2</sup> , <sup>1</sup> <i>Animal Health and Veterinary Laboratories Agency, UK</i> , <sup>2</sup> <i>University of Liverpool, UK</i>	
15:10 – 15:30	<b>Closing Summary, Co-chairs, VC7 and Co-chair, VC8</b>	

**The final poster programme can be found on the information board**

Poster Session 1 will take place on Sunday 27 October at 18:00-19:00 for all the odd numbers (P1, P3, P5 etc.)

Poster Session 2 will take place on Monday 28 October at 14:30-15:30 for all the even numbers (P2, P4, P6 etc.)

**Please turn over for the final breaking news**

# Breaking News

## Invited Speaker Biography



**Rino Rappuoli** is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics and is based in Siena, Italy. He earned his PhD in Biological Sciences at the University of Siena and has served as visiting scientist at Rockefeller University in New York and Harvard Medical School in Boston. Prior to the present position he was head R&D of Sclavo and then head of vaccine research and Chief Scientific Officer of Chiron Corporation.

Several molecules he worked with became part, or are near to becoming, licensed vaccines. These include: *CRM197* used in *H.influenzae*, *N.meningitidis*, and pneumococcus vaccines; an acellular vaccine against pertussis containing a genetically detoxified pertussis toxin; the first *conjugate vaccine* against *meningococcus C* and later against *meningococcus ACYW*; the MF59 used in a vaccine against pandemic influenza; and the genome-derived vaccine against *meningococcus B* for which in November 2012 the European Medicinal Agency recommended the granting of a marketing authorization, the first vaccine to provide broad coverage against meningococcal serogroup B. This was followed by the approval of the European Commission in January 2013. In August 2013 the vaccine was approved by the Australian Register of Therapeutic Goods (ARTG) for use in individuals from two months of age and older.

He was elected member of the US National Academy of Sciences and the European Molecular Biology Organization. Awards conferred include: Paul Ehrlich and Ludwig Darmstaedter Prize (1991), the Gold Medal by the Italian President (2005), the Albert B. Sabin Gold Medal (2009), the Lifetime Achievement Award from the Institute of Human Virology in Maryland (2010), and the Excellence Award from the European Society of Clinical Microbiology and Infectious Diseases (2011). In 2013 he was nominated third most influential person worldwide in the field of vaccines (Terrapin).

He has introduced several novel scientific concepts (*genetic detoxification, 1987, cellular microbiology, 1996; reverse vaccinology, 2000; pangenome, 2005*).

## Poster Programme

### New Posters

These poster abstracts can be found online

[P224]	<b>Set up of pseudotype-based inhibition assay for the detection of functional antibodies to Influenza virus neuraminidase</b> M. Prevato* <sup>1</sup> , A. Nandi <sup>3</sup> , A. Lilja <sup>3</sup> , F. Giusti <sup>1</sup> , I. Ferlenghi <sup>2</sup> , E. Montomoli <sup>1</sup> , F. Legay <sup>2</sup> , A. Bonci <sup>2</sup> , <sup>1</sup> University of Siena, Italy, <sup>2</sup> Novartis, Italy, <sup>3</sup> Novartis, USA
[P225]	<b>The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses</b> D.O. Villarreal*, D.B. Weiner, <i>University of Pennsylvania, USA</i>
[P226]	<b>HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo</b> K. Muthumani <sup>1</sup> , K. Broderick <sup>2</sup> , N. Hutnick <sup>1</sup> , M. Wise <sup>1</sup> , J. Yan <sup>2</sup> , J. Mendoza <sup>2</sup> , C. Tingey <sup>1</sup> , S. Flingai <sup>1</sup> , N. Sardesai <sup>2</sup> , D. Weiner* <sup>1</sup> , <sup>1</sup> University of Pennsylvania School of Medicine, USA, <sup>2</sup> Inovio Pharmaceuticals Inc, USA

This poster abstract can be found in the late news inside your bag

[P227]	<b>The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) Initiative: Progress, lessons learned and priorities for the future</b> A. Adjagba* <sup>3</sup> , J. Chaccour <sup>2</sup> , R. Biellik <sup>2</sup> , K. Senouci <sup>1</sup> , P. Duclos <sup>1</sup> , B. Gessner <sup>3</sup> , <sup>1</sup> World Health Organization IVB, Switzerland, <sup>2</sup> Independant Consultant, Switzerland, <sup>3</sup> Agence de Médecine Préventive, France
--------	--

The following abstract was withdrawn but has been reinstated

[P030]

Change in presenting author

[P089] will be presented by T. Nolan  
[P189] will be presented by M. Gallotta

Poster Withdrawals

[P039] & [P215]